Ria Kakkad (Drug Target Review)2023-04-11T10:00:40
New research from Cincinnati Children’s Hospital Medical Center suggests blocking IL-22 and IL-1R could offer a promising IBD treatment.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2024-01-24T12:52:38
Sponsored by BellBrook Labs
2026-05-22T07:38:00
Contributor Dr Helen Bright, Drug Target Review
2023-03-07T10:55:58
Sponsored by Agilent
2026-03-25T15:00:00
Sponsored by Yokogawa
2023-04-04T15:03:09
Sponsored by Agilent
2023-02-13T11:57:11
Sponsored by Agilent
Site powered by Webvision Cloud